Nkarta (NKTX) investor relations material

Transforming autoimmune disease treatment

• Engineered natural killer (NK) cells are being developed to address major unmet needs in autoimmune diseases, aiming for drug-free remission and improved patient outcomes.

• Off-the-shelf, donor-derived NK cell therapies are designed for outpatient dosing, increasing accessibility and scalability for patients.

• NKX019, a CD19 CAR NK cell product, is engineered for enhanced activation, persistence, and optimal target cell killing, with a proprietary humanized CD19 binder and OX40 costimulatory domain.

Clinical and preclinical evidence

• NKX019 demonstrates superior killing of CD19+ cells compared to CAR T therapy, including low CD19-expressing cells, and traffics to multiple tissues.

• Clinical responses in oncology studies show no increase in proinflammatory cytokines, with no observed ICANS or life-threatening CRS.

• NKX019 depletes and resets the B cell compartment, with deep suppression and reconstitution of naïve B cells, supporting an "immune reset".

• In vitro studies confirm NKX019's consistent B cell killing across multiple autoimmune indications, including lupus, myositis, scleroderma, and rheumatoid arthritis.

Safety, accessibility, and logistical advantages

• Off-the-shelf CAR NK cells offer outpatient dosing, on-demand availability, and a favorable safety profile with low risk of CRS or ICANS.

• Avoids logistical burdens and toxicity associated with autologous CAR T cell therapy, such as manufacturing delays and need for inpatient monitoring.